Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials by Bang, J et al.
Predicting Disease Progression in Progressive Supranuclear 
Palsy in Multicenter Clinical Trials
Jee Bang#a, Iryna V. Lobach#b, Anthony E. Langc, Murray Grossmand, David S. Knopmane, 
Bruce L. Millera, Lon S. Schneiderf, Rachelle S. Doodyg, Andrew Leesh, Michael Goldi, 
Bruce H. Morimotoj, Adam L. Boxera,§, and on behalf of the AL-108-231 Investigators
aMemory and Aging Center, Department of Neurology, University of California San Francisco, 675 
Nelson Rising Lane, Suite 190, San Francisco, CA, USA 94158.
bDepartment of Epidemiology and Biostatistics, Division of Biostatistics, University of California 
San Francisco, 550 16th Street, San Francisco, CA, USA 94158. iryna.lobach@ucsf.edu
§Corresponding author: Dr. Adam Boxer, Memory and Aging Center, Department of Neurology, University of California, San 
Francisco, 675 Nelson Rising Lane, Suite 190, San Francisco, CA 94158, USA, adam.boxer@ucsf.edu, 415-476-0668.
jee.bang@ucsf.edu
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Financial Disclosure/Conflict of Interest: None
Financial Disclosures of All Authors:
Jee Bang: none
Iryna Lobach: none
Anthony Lang: none
Murray Grossman: none
David Knopman: none
Bruce Miller: none
Lon Schneider: none
Rachelle Doody: none
Andrew Lees: none
Michael Gold: none
Bruce Morimoto: none
Adam Boxer: Dr. Boxer receives research support from Avid, Bristol Myers Squibb, C2N Diagnostics, Cortice Biosciences, Eli Lilly, 
Forum Pharmaceuticals, Genentech and TauRx. He has served as a consultant for Abbvie, Asceneuron, Ipierian, Ionis and Merck. He 
has stock/options in Alector and Delos.
Author's Roles
Jee Bang: Drafting/revising the manuscript for content, including medical writing for content, study concept/design, analysis/
interpretation of data.
Iryna Lobach: Statistical analysis, drafting/revising the manuscript for content, including medical writing for content, study concept/
design, analysis/interpretation of data.
Anthony Lang: Drafting/revising the manuscript for content.
Murray Grossman: Drafting/revising the manuscript for content.
David Knopman: Drafting/revising the manuscript for content.
Bruce Miller: Drafting/revising the manuscript for content.
Lon Schneider: Drafting/revising the manuscript for content.
Rachelle Doody: Drafting/revising the manuscript for content.
Andrew Lees: Drafting/revising the manuscript for content.
Michael Gold: Drafting/revising the manuscript for content.
Bruce Morimoto: Drafting/revising the manuscript for content.
Adam Boxer: Drafting/revising the manuscript for content, including medical writing for content, study concept/design, analysis/
interpretation of data.
HHS Public Access
Author manuscript
Parkinsonism Relat Disord. Author manuscript; available in PMC 2017 July 01.
Published in final edited form as:
Parkinsonism Relat Disord. 2016 July ; 28: 41–48. doi:10.1016/j.parkreldis.2016.04.014.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cDepartment of Neurology, University of Toronto, 399 Bathurst St, McLaughlin 7-418, Toronto, ON, 
M5T 2S8, Canada. lang@uhnresearch.ca
dDepartment of Neurology, University of Pennsylvania, 3400 Spruce St, Philadelphia, PA, USA 
19104. mgrossma@mail.med.upenn.edu
eDepartment of Neurology, Mayo Clinic, 200 1st St SW, Rochester, MN, USA 55905. 
knopman@mayo.edu
fDepartment of Psychiatry and the Behavioral Sciences and Department of Neurology, Keck 
School of Medicine of the University of Southern California, Los Angeles, CA, USA. 
lschneid@usc.edu
gDepartment of Neurology, Baylor College of Medicine, 6550 Fannin St # 1801, Houston, TX, 
USA 77030. rdoody@bcm.edu
hInstitute of Neurology, University College of London, 1 Wakefield Street - London - WC1N 1PJ, 
UK. alees@ion.ucl.ac.uk
iUCB BioSciences, Research Triangle, NC, USA. michael.gold.md@gmail.com
jCelerion, 621 Rose St, Lincoln, NE 68502, USA. bhmorimoto@gmail.com
#
 These authors contributed equally to this work.
Abstract
 Introduction—Clinical and MRI measurements can track disease progression in PSP, but 
many have not been extensively evaluated in multicenter clinical trials. We identified optimal 
measures to capture clinical decline and predict disease progression in multicenter PSP trials.
 Methods—Longitudinal clinical rating scales, neuropsychological test scores, and volumetric 
MRI data from an international, phase 2/3 clinical trial of davunetide for PSP (intent to treat 
population, n=303) were used to identify measurements with largest effect size, strongest 
correlation with clinical change, and best ability to predict dropout or clinical decline over one 
year as measured by PSP Rating Scale (PSPRS).
 Results—Baseline cognition as measured by Repeatable Battery for Assessing 
Neuropsychological Status (RBANS) was associated with attrition, but had only a small effect. 
PSPRS and Clinical Global Impression (CGI) had the largest effect size for measuring change. 
Annual change in CGI, RBANS, color trails, and MRI midbrain and ventricular volumes were 
most strongly correlated with annual PSPRS and had the largest effect sizes for detecting annual 
change. At baseline, shorter disease duration, more severe depression, and lower performance on 
RBANS and executive function tests were associated with faster worsening of the PSPRS in 
completers. With dropouts included, SEADL, RBANS, and executive function tests had significant 
effect on PSPRS trajectory of change.
 Conclusion—Baseline cognitive status and mood influence the rate of disease progression in 
PSP. Multiple clinical, neuropsychological, and volumetric MRI measurements are sensitive to 
change over one year in PSP and appropriate for use in multicenter clinical trials.
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 Introduction
Progressive supranuclear palsy (PSP) is a fatal neurodegenerative disease characterized by 
the aggregation of predominantly 4 microtubule binding domain repeat (4R) tau in neurons 
and glia. [1] There are several clinical presentations of PSP [2, 3] and Richardson's 
syndrome is the most recognizable and rapidly progressive phenotype, characterized by 
early and severe gait instability with falls, slowed eye movements progressing to 
supranuclear ophthalmoplegia, axial rigidity, and variable neuropsychiatric symptoms. There 
are no effective therapies for PSP; however, a variety of new potential treatments targeting 
tau are entering clinical trials. [4]
The feasibility of conducting pivotal clinical trials in PSP was recently demonstrated in three 
large, international studies. [5-7] A variety of clinical rating scales (such as PSP Rating 
Scale; PSPRS[8] and volumetric MRI measurements have been developed and validated for 
use in PSP based on small, single center studies and then applied to large, international 
clinical trials with little evidence to support their utility in multicenter settings. We examined 
data from the 48 center, randomized, placebo controlled phase 2/3 clinical trial of davunetide 
for PSP (AL-108-231) [6] to identify the best baseline clinical and biomarker outcome 
measures that: 1) capture clinical decline and 2) predict attrition or disease progression over 
one year.
 Methods
 Source of data
The data for this study were taken from the previously reported AL-108-231 
(clinicaltrials.gov, NCT 01110720) international, randomized, double-blind, placebo-
controlled, phase 2/3 trial of davunetide for PSP [6]. The study enrolled 313 patients with 
PSP (Richardson's syndrome) at 48 centers in Australia, Canada, France, Germany, the 
United Kingdom and the United States. The intent to treat population (n=303) of individuals 
who were randomized to davunetide or placebo and had at least one post-baseline 
assessment of both primary and secondary outcomes was used for analyses of baseline 
variables that predicted dropout.
 Inclusion criteria
To be included in the AL-108-231 study, participants had to meet modified criteria for 
probable or possible PSP based on the Neuroprotection and Natural History in Parkinson 
Plus Syndromes (NNIPPS) study. [5] Individuals had to be between 41-85 years of age at 
disease onset with at least a 12-month history of early and prominent postural instability or 
falls, supranuclear ophthalmoplegia or decreased downward saccade velocity, and prominent 
axial rigidity. Participants were required to be able to either ambulate independently or take 
at least five steps with minimal assistance. Individuals could participate only if they had PSP 
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symptoms for less than 5 years, or if for more than 5 years with a PSPRS of 40 or greater at 
screening. Detailed inclusion and exclusion criteria are described in the primary study 
manuscript. [6]
 Clinical data
The primary endpoints were the change in PSPRS and Schwab and England activities of 
daily living scale (SEADL) [9] over one year. The PSPRS consists of six categories 
including daily activities, behavior, bulbar, oculomotor, limb motor, and gait/midline. Scores 
range from 0 to 100, with higher scores indicating more severe disease. SEADL is a measure 
of overall disability based on interviews with the patient and the informant, and is scored on 
an 11-point ordinal scale (10% intervals starting with 0 indicating vegetative functions, up to 
100% indicating complete independence).
Secondary outcome measures included the Clinical Global Impression of Change (CGIC) 
[10] and brain ventricular volume as measured on MRI scans as described below. [6] In 
addition, exploratory outcomes were obtained including: the Repeatable Battery for the 
Assessment of Neuropsychological Status (RBANS; test domains inlcude memory, 
visuospatial, language, and attention) [11], three additional assessments of executive 
function (color trails, phonemic fluency, and letter-number sequencing), the Geriatric 
Depression Scale (GDS), [12] the Clinical Global Impression of Disease Severity (CGIds) 
[13], and additional volumetric MRI scan measurements of the whole brain, midbrain, and 
superior cerebellar peduncle (SCP). A total of 217 patients completed the 
neuropsychological testing.
 MRI data (n=214)
To be included in the clinical trial all participants had to complete a baseline volumetric T1-
weighted MRI scan on a 1.5T or 3T scanner. Whole brain and ventricular volumes were 
generated using the boundary shift integral technique, and midbrain and SCP volumes were 
generated using label propagation in statistical parametric mapping 5 (SPM5) at the Mayo 
Clinic Aging and Dementia Imaging Research Laboratory as previously described [6]. Brain 
volumes were adjusted for total intracranial volume (TIV) to control for head size 
differences where appropriate. Pons volume was not obtained. All scanners were calibrated 
using a standard phantom and MRI analyses were conducted blinded to treatment 
assignment. Five subjects were excluded from the original dataset (n=219), because they 
were deemed to be influential outliers (well below the 25th or far above the 75th percentile 
of annual change), likely due to artifacts introduced during the initial MRI analysis.
 Statistical Analysis
We combined data from the placebo and davunetide groups since extensive analyses of the 
davunetide trial dataset revealed no differences between groups at baseline. The absolute 
value of Cohen's d between the treatment arms for baseline demographics, primary and 
secondary outcomes ranged [0.01, 0.14]; for MRI measures [0.01, 0.07], and in change in 
measures over time for primary and secondary outcomes ranged [0.01, 0.24]; and for change 
in MRI measures [0.01, 0.15]. Baseline values and 52-week change from baseline values in 
clinical ratings, neuropsychological measures, and MRI volumes were presented using 
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estimates of central tendency (mean, proportion) and variance. Effect of baseline 
characteristics on drop out was examined using logistic regression models. Concordance 
between the observed 52-week change in PSPRS and the corresponding change in other 
measures was measured using Pearson R2 and Spearman correlation coefficients where 
appropriate. All estimates include 95% confidence intervals. The relationship of the baseline 
evaluations to the 52-week change in PSPRS was explored with univariate and multivariate 
linear regression models. These models were performed with and without adjustments for 
potential confounders: baseline PSPRS, age, gender, disease duration, treatment group 
assignment (davunetide or placebo), tau haplotype, CoQ10 use, and MMSE.
We further examined the effect of baseline evaluations on trajectory of PSPRS across all 
patients using linear mixed effects models. These models accommodate repeated measures 
of PSPRS and allow the baseline evaluations to have impact on the overall trajectory both in 
slope (speed of PSPRS change) and intercept. The random coefficients model that we 
employed includes two random variables allowing shift in the overall trajectory and 
modification of the speed of PSPRS change due to patient-specific characteristics.
To investigate the ability of the baseline evaluations to define subpopulations with either a 
faster rate or smaller standard deviation of change in PSPRS, a minimum p-value method 
and sample size/power analyses were performed. The search for a cut-off was performed on 
an equally spaced grid of values ranging from minimum to maximum of a baseline measure. 
The goal of this search was to find a cut-off that separated the population into two 
subpopulations with significantly different speeds of progression as measured by the two-
sided, two-sample Student's t-test of the 52-week change in PSPRS. If multiple cut-offs 
resulted in significant separation (p <0.05), final cut-offs were chosen to be the ones that 
defined clinically relevant subpopulations with maximum effect size (PSPRS/SD[PSPRS]). 
Longitudinal behavior of PSPRS in the inferred subpopulations is presented based on 
average changes modeled at 13, 26, 39, and 52 week follow-up visits, accompanied by 
standard error values. Sample size analyses were performed to estimate minimum sample 
sizes required to detect 10%, 25%, 37.5%, and 50% change in PSPRS progression 
attributable to the treatment effect with 90% power using two-sample Student's t-test at the 
two-sided 0.05 significance level, not accounting for dropout or accounting for the observed 
23% dropout rate from the AL-108-231 study. The proportion of inter-patient variability in 
change of PSPRS explained by multivariate regression models was broken down into 
portions corresponding to each variable using analyses of relative importance. [14] False 
discovery rate (FDR) adjustment was applied to correct for multiple testing [15].
 Standard Protocol Approvals, Registrations, and Patient Consents
Ethics approval was obtained at each site from the local ethics committee and all participants 
gave written informed consent at the recruitment visit as per local regulations.
Bang et al. Page 5
Parkinsonism Relat Disord. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
 Results
 Baseline characteristics of AL-108-231 trial completers
The baseline characteristics of the davunetide trial participants are shown in Table 1. 
Baseline characteristics of the participants with complete 52-week PSPRS data (n=241) did 
not substantially differ from the overall population (n=303) used for the primary, intent to 
treat analyses [6]. The baseline characteristics of the participants who dropped out (n = 62) 
were similar to those of completers. However, participants with worse cognitive function at 
baseline (RBANS scores) had slightly higher risk of dropping out (RR=1.05 [95% CI: 1.02, 
1.08]). There were no other characteristics that differed between individuals who dropped 
out or completed the trial.
 Correlation of changes in outcome measures with change in PSPRS
Of the clinical scales, the largest effect sizes (Cohen's d) for change over 52 weeks were 
observed with the PSPRS and CGIC in the trial completers (Table 2). As expected, the two 
primary outcome measures, the PSPRS and SEADL, showed concordant declines over one 
year. Other clinical (CGIds, CGIC, GDS) and neuropsychological (RBANS Total Raw and 
Total Scaled, Letter Number Sequence) outcomes changed over one year and these declines 
also correlated with changes in PSPRS. Midbrain volume (absolute change and percent 
change), ventricular volume (percent change), and whole brain volume (percent change) had 
the largest effect sizes for 52 week change and were correlated with changes in PSPRS.
 Individual baseline predictors of clinical progression
In the trial completers, the baseline values for a variety of clinical outcome measures, 
including disease duration, GDS, RBANS, and color trails 1 and 2 were strongly related to 
52-week change in PSPRS (Table 3) with adjustment for baseline PSPRS, and other 
potential confounding variables including age, gender, disease duration, treatment group 
assignment (davunetide or placebo), tau haplotype, CoQ10 use, and MMSE. Using linear 
mixed effect models, we further examined the effect of baseline measurements on trajectory 
of PSPRS change of all participants including completers and dropouts with adjustments for 
patient-specific characteristics, including potential confounders (Table 4). The following 
baseline evaluations had significant effect on both the intercept and slope (speed of change) 
of PSPRS trajectory: color trails 2 (z=3.2), color trails 1 (z=3.09), phonemic fluency (z=
−2.9), RBANS [z=−2.32(scaled) and z=−2.28(raw)] and SEADL (z=−2.06).
 Multivariate models predicting clinical progression
The ability of multiple baseline characteristics to explain inter-patient variability in change 
of PSPRS was examined using multivariate regression models. We found that a model that 
combined baseline demographic, clinical, and neuropsychological measures (PSPRS, color 
trails 2, GDS, total raw RBANS score, phonemic fluency), and potential confounders (age, 
disease duration, treatment group, co-enzyme Q10 use) explained 16.4% of variance in 52-
week PSPRS change (Model 1; Supplementary Table 1). In this model (N=226), disease 
duration [β = −5.77 (−10.1, −1.4)] and GDS [β =0.24 (0.06, 0.41)], were significant 
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contributors. Adding volumetric MRI measurements to this model (Model 2; N=213) did not 
improve the ability to explain variance in 52-week PSPRS change.
 Utility of baseline values in determining sample size of hypothetical clinical trials
We determined the estimated number of patients per arm in a two-arm parallel study 
required to demonstrate an effect of a hypothetical treatment for PSP in slowing the rate of 
change in PSPRS scores over 52 weeks, assuming all participants completed the trial 
(Supplementary Table 2). The planned AL-108-231 sample size (n=150 per arm) was based 
on the number required to detect a treatment effect of a 37.5% difference in rate of decline in 
PSPRS over one year based on the published rate of PSPRS change (11±11 points) at a 
single center [8] with 90% power at α = 0.05. However, using the observed rate of PSPRS 
change in the patients who completed the study (11±9 points), only 106 patients per arm 
would be required to detect this treatment effect.
Using a minimum p-value approach, we identified cut points in baseline values that could 
define sub-populations with significantly different rates of change in PSPRS over one year 
based on the observed data. For example, baseline phonemic fluency values defined 
subpopulations with faster rates of PSPRS change than the overall population, leading to a 
reduction in sample size required to detect a treatment effect (Supplementary Table 2). Other 
cut points defined subpopulations with slower rates of change than the overall population, 
such as individuals with disease duration at baseline of greater than 5 years.
 Discussion
We found that PSPRS, CGIC, CGIds and RBANS were the best clinical measurements, and 
midbrain and ventricular volume were the best MRI measurements for capturing 
longitudinal change in PSP in a large, international clinical trial. These measurements had 
comparable effect sizes for measuring change; however, fewer high quality MRI data were 
available for analysis after one year which might limit the utility of this measurement. 
Baseline cognitive status had a small effect on predicting patient attrition. In the trial 
completers, disease duration, baseline measures of depression (GDS), RBANS, and color 
trails scores were significantly associated with annual changes in PSPRS scores. Patients 
with longer disease duration at baseline had a slower rate of progression. This might 
possibly be because they initially had variant forms of PSP such as pure akinesia with gait 
freezing (PAGF) or PSP parkinsonism (PSP-P) preceding their evolution into Richardson's 
syndrome at study entry. PAGF and PSP-P are known to have slower rates of progression 
than Richrdson's syndrome [22]. In the overall population, SEADL, RBANS, and executive 
function tests were the strongest predictors of PSPRS change. Multivariate models that 
included baseline clinical and MR imaging variables were no better at explaining variance in 
annual PSPRS change than individual variables. Together, these results demonstrate that a 
number of clinical and imaging biomarkers are sensitive to change in a typical, multicenter 
PSP clinical trial population. Volumetric MRI measurements are likely to be informative, but 
did not provide substantially greater power to detect change than clinical rating scales.
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 Measuring longitudinal change in PSP clinical trials
After the NNIPPS study, [5] the AL-108-231 study was the largest multicenter clinical trial 
that has been completed in PSP. Although there was little experience with use of the PSPRS 
in a multicenter clinical trial setting prior to this study, the current analyses show that this 
measure and the CGIC (a secondary outcome measure for the trial) were the best clinical 
scales for measuring disease progression, based on Cohen's d, over one year. 
Neuropsychological testing and MRI changes also showed modest correlations with changes 
in PSPRS. Based on effect size of change over one year and strength of correlation with 
change in PSPRS, midbrain volume seemed to be the most promising of the MRI volumetric 
measures for tracking disease progression. Similar to a smaller, single center study [16], all 
four region of interest volumes examined from MRIs collected from 48 different clinical 
centers were to some extent correlated with clinical change, although baseline volumes were 
not related to annual PSPRS change in trial completers. Importantly, the standard deviation 
of change in PSPRS score over one year in the AL-108-231 trial was less than previously 
reported, which resulted in greater power to detect a treatment effect than originally planned 
(Supplementary Table 2).
We identified a number of other clinical measures that could predict clinical decline in PSP, 
even after controlling for baseline disease severity and other potential confounding factors. 
Executive function is often the only reported neuropsychological deficit in the typical PSP 
(Richardson's) syndrome, [17-19] and individuals with worse color trails scores, a measure 
of executive function, declined at a faster rate. Surprisingly, the broader RBANS 
neuropsychological battery which includes tests of memory, attention, language and 
visuospatial function was also sensitive to change over one year, and individuals with more 
global cognitive impairments on RBANS at baseline had higher rates of annual PSPRS 
change. Depression and apathy are prominent in PSP, [20, 21] and we found that more 
severe baseline depression on the GDS was also associated with faster rates of PSPRS 
change. We identified cutoff values that could be used as selection criteria that could be used 
in a future study to define populations with more rapid or predictable disease progression.
 Reducing attrition rate to improve power
Since patient drop out and a lack of evaluable data can diminish the power and quality of a 
trial, we first analyzed the baseline characteristics of study completers and dropouts, and 
found that there were no baseline characteristics that had a significant and meaningful effect 
on trial completion (Table 1). While dropouts had lower baseline RBANS scores than 
completers, the odds ratio for completing the trial based on RBANS was small (1.05). This 
suggests that in a PSP population similar to those recruited for the AL-108-231 trial, there 
are few changes to enrollment criteria that would have a major effect on study completion. 
Therefore it may be better to focus on other aspects of clinical trial procedures to identify 
ways to decrease attrition.
 Limitations of current study
We combined data from the AL-108-231 study's treatment and placebo groups, which could 
have influenced the results if there was an undetected effect of the treatment (davunetide). 
This seems unlikely since the original trial analyses failed to identify an effect of treatment 
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on any of the outcomes in either the primary intent-to-treat, completer, or a number of 
sensitivity analyses. Moreover, our analyses controlled for treatment group assignment.
 Conclusion
We identified clinical and MRI measures that were able to capture change in a diverse 
population of PSP patients, and whose baseline values also related to clinical decline over 
the course of a year in a large multicenter trial. Together, these data provide support for 
inclusion of specific scales and imaging tools in future PSP clinical trials.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Baseline cognitive status and mood influence rate of disease progression in 
PSP
• No significant differences were found in those who dropped out vs. 
completers
• Clinical, neuropsychological, and MRI measurements are sensitive to 
change in PSP
• The same measurements are appropriate for use in future multicenter 
clinical trials
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Table 1
Baseline characteristics of completers and dropouts
Value
Completers Dropouts Completers vs Dropouts
Mean (95% Confidence Interval) or Count (%) Relative Risk* (95% Confidence 
Interval)
Demographics N=241 N=62
Age years 67.4 (66.5, 68.1) 68.6 (66.9, 70.2) 0.99 (0.94, 1.02)
Sex female 125 (51.9%) 27 (43.5%) 0.85 (0.47, 1.5)
Weight kg 78.4 (76.2, 80.2) 74.1 (69.9, 78.4) 1.03 (1.01, 1.06)
Race White 214 (88.8%) 52 (83.9%) 1.1 (1.0, 1.2)
MMSE 26.5 (26.1, 26.9) 25.5 (24.5, 26.4) 1.1 (1.0, 1.2)
Treatment Davunetide 118 (49%) 30 (48.4%) 1.1 (0.60, 1.9)
Tau haplotype n (% genotyped) H1/H1 181 (95.8%) 47 (75.8%) 0.67 (0.34, 1.3)
H1/H2 8 (4.2%) 5 (8.1%)
H2/H2 0 (0%) 0 (0%)
Missing 52 (21.6%) 10 (16.1%)
Disease duration % > 5 years 19 (8.4%) 8 (12.9%) 0.63 (0.25, 1.7)
Concomitant medication used during study N=241 N=62
CoQ10 use 49 (20.3%) 11 (17.7%) 1.1 (0.52, 2.4)
Levodopa use 111 (46.1%) 26 (41.9%) 1.2 (0.64, 2.1)
Primary outcomes N=241 N=62
PSPRS 39.1 (37.7, 40.5) 41.2 (38.7, 43.7) 0.99 (0.96, 1.02)
SEADL 0.54 (0.51, 0.57) 0.46 (0.41, 0.51) 3.48 (0.52, 24.0)
Secondary/exploratory outcomes N=241 N=62
GDS 12.7 (11.8, 13.6) 12.6 (11.1, 12.6) 1.01 (0.97, 1.06)
CGIds 3.9 (3.8, 4.0) 4.2 (3.9, 4.4) 0.78 (0.53, 1.2)
RBANS Total raw 144.9 (140.7, 149.1) 128 (119.7, 136.3) 1.02# (1.00, 1.03)
Total scaled 74.4 (72.8, 76.0) 67.6 (64.7, 70.4) 1.05# (1.02, 1.08)
Phonemic Fluency Words/min 11.5 (10.6, 12.4) 9.6 (8.0, 11.1) 1.03 (0.98, 1.08)
Letter number seq. Score 7.1 (6.7, 7.5) 6.1 (5.4, 6.8) 1.06 (0.93, 1.2)
Color Trails 1 Seconds 160.5 (151.6, 169.4) 189.2 (173, 205.4) 0.99 (0.99, 1.0)
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Value
Completers Dropouts Completers vs Dropouts
Mean (95% Confidence Interval) or Count (%) Relative Risk* (95% Confidence 
Interval)
Color Trails 2 Seconds 235 (226, 244) 262.2 (246, 278.4) 0.99 (0.99, 1.0)
MR Imaging N=223 N=58
Ventricular volume/TIV ×10−4 333.1 (315.6, 357.1) 330.8 (295.8, 365.7) 1.0 (0.99, 1.0)
Whole brain volume/TIV ×10−4 9,008 (8949, 9067) 8,827 (8716, 8938) 1.0 (0.99, 1.0)
Midbrain volume/TIV ×10−4 46.9 (46.2, 47.7) 51 (48, 53) 1.0 (0.99, 1.0)
SCP volume/TIV ×10−4 2.6 (2.5, 2.7) 2.5 (2.3, 2.8) 1.0 (0.99, 1.0)
MMSE= Mini Mental Status Exam; PSPRS=Progressive Supranuclear Palsy Rating Scale; SEADL= Schwab and England Activities of Daily 
Living Scale; GDS= Geriatric Depression Scale; CGIds= Clinical Global Impression of Disease Severity; RBANS= Repeatable Battery for the 
Assessment of Neuropsychological Disease Status; SCP= superior cerebellar peduncle; TIV= total intracranial volume.
*Adjusted for PSPRS, age, gender, disease duration, treatment group assignment (davunetide or placebo), tau haplotype, CoQ10 use, and MMSE.
#p<0.05 (FDR corrected)
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Table 3
Regression of the baseline values on 52-week change in PSPRS in completers
Baseline characteristics Univariate Slope (95% Confidence Interval) Adjusted for multiple baseline characteristics‡ Slope 
(95% Confidence Interval)
Demographics
Age −0.21 (−0.39, −0.02) −0.14 (−0.33, 0.04)
Sex −0.25 (−2.6, 2.1) 0.88 (−1.5, 3.2)
Weight −0.04 (−0.11, 0.04) −0.07 (−0.17, 0.02)
Tau haplotype
H1/H1 −1.2 (−4.1, 1.7) −1.0 (−4.0, 2.0)
H1/H2 −2.0 (−9.0, 5.0) −1.3 (−8.0, 5.4)
Treatment/Medication Use
Davunetide −0.44 (−2.8, 1.9) −0.74 (−3.1, 2.6)
CoQ10 use 2.4 (−0.58, 5.3) 1.7 (−1.2, 4.5)
Levodopa use −0.13 (−2.5, 2.3) −0.81 (−3.2, 1.5)
Clinical
Disease Duration
−8.2 (−12.3, −4.1)* −8.2 (−12.5, −3.9)*
PSPRS −0.05 (−0.16, 0.06) 0.00 (−0.12, 0.12)
SEADL −3.1 (−8.5, 2.3) −6.0 (−13.6, 1.6)
GDS 0.21 (0.04, 0.38) 0.26 (0.08, 0.44)*
CGIds −0.41 (−1.7, 0.91) −0.18 (−1.7, 1.4)
MMSE −0.13 (−0.49, 0.23) −0.11 (−3.1, 1.6)
RBANS Total raw −0.04 (−0.08, −0.008)
−0.07 (−0.12, −0.02)*
RBANS Total scaled −0.11 (−0.20, −0.02) −0.12 (−0.23, 0.003)
Fluency Words/min
−0.25 (−0.42, −0.08)* −0.24 (−0.42, −0.06)
Letter number Score −0.32 (−0.73, 0.09) −0.37 (−0.88, 0.15)
Color Trails 1 Seconds 0.03 (0.01, 0.04)* 0.03 (0.01, 0.05)*
Color Trails 2 Seconds 0.03 (0.01, 0.04)* 0.04 (0.01, 0.05)*
MR Imaging
Ventricular volume/TIV −6 (−95.5, 83.5) 9.1 (−86.2, 104.3)
Whole brain volume/TIV −25 (−51.7, 1.6) −32.1 (−61.6, −2.6)
Midbrain volume/TIV −1762 (−4157, 632) −1758 (−4274, 758)
SCP volume/TIV (×103) −17.1 (−33.1, −1.1) −19.6 (−36.0, −2.3)
Abbreviations: PSPRS=PSP Rating Scale; SEADL=Schwab and England Activities of Daily Living Scale; GDS=Geriatric Depression Scale; 
CGIds=Clinical Global Impression of Disease Severity; RBANS=Repeatable Battery for the Assessment of Neuropsychological Disease Status; 
SCP=superior cerebellar peduncle; TIV=total intracranial volume.
‡
Linear regression adjusted for baseline PSPRS, age, gender, disease duration, treatment group assignment, tau haplotype, CoQ10 use, and MMSE.
*p<0.05 (FDR corrected).
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Table 4
Effect of baseline measurements on the trajectory of PSPRS change using linear mixed effect models.
Baseline characteristics
Mixed Effects Model
Fixed portion Random portion estimate (SE)
Term Z-score Coefficient p Intercept Slope
SEADL Time 9.4 0.28 0.001 59.1 (5.3) 0.02 (0.003)
SEADL −16 −34 <0.001
SEADL × Time −2.06 −0.11 0.045
Color Trails 1 Time 5.0 0.14 <0.001 87.4 (7.6) 0.02 (0.003)
CCT1 9.5 0.08 <0.001
CCT1 × Time 3.09 0.0005 0.006
Color Trails 2 Time 2.7 0.10 0.007 91.6 (8.0) 0.02 (0.003)
CCT2 8.5 0.07 <0.001
CCT2 × Time 3.2 0.0005 0.005
RBANS raw Time 6.8 0.32 <0.001 83.5 (7.2) 0.02 (0.003)
RBANS −10.2 −0.16 <0.001
RBANS × Time −2.28 −0.0007 0.04
RBANS scaled Time 5.7 0.36 <0.001 94.2 (8.1) 0.02 (0.003)
RBANS −7.8 −0.34 <0.001
RBANS × Time −2.32 −0.002 0.03
Phonemic Fluency Time 12.9 0.27 <0.001 102.1 (8.7) 0.02 (0.003)
PHON FLU −6.1 −0.53 <0.001
PHON FLU × Time −2.9 −0.005 0.01
SEADL= Schwab and England Activities of Daily Living Scale; RBANS= Repeatable Battery for the Assessment of Neuropsychological Disease 
Status
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